Medco "Genetics For Generics" Research Anticipates Plavix Patent Loss
Medco is working to generate cost effectiveness data for Bristol-Myers Squibb's anti-clotting blockbuster Plavix in anticipation of the launch of clopidogrel generics in 2011
You may also be interested in...
Express Scripts’ caution about the cost effectiveness of some genetic testing could hint at how interested it will be in continuing the pharmacogenomic programs sponsored by former rival PBM Medco, which Express acquired in early April.
The multi-year, global data, research and consulting agreement will focus primarily on drugs in Phase II or III.
The role of newer antiplatelet agents such as Effient (prasugrel) is partly dependent on the prospects for optimizing Plavix (clopidogrel), but the feasibility of using diagnostic tests to make sure the soon-to-be generic drug is working properly remains a matter of debate in cardiology.